Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib — Masatoshi Kudo (2022) | RDL Network
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
Andrew X. Zhu, Richard S. Finn, Stéphane Cattan, Julien Edeline, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Olivier Rosmorduc, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Scot Ebbinghaus, Junshui Ma, Abby B. Siegel, Ann‐Lii Cheng, Masatoshi Kudo
Masatoshi Kudo, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Lætitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Ellen B. Gurary, Abby B. Siegel, Lokesh Jain, Ann‐Lii Cheng, Andrew X. Zhu
Peter Vogel, Julien Edeline, Sadahisa Ogasawara, Masatoshi Kudo, R. Finn, D. Palmer, Chris Verslype, Vittorina Zagonel, L. Fartoux, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Aristine Cheng, B. Daniele, T. Yau, A. Wang, Ken Hatogai, A.B. Siegel, S. Cattan
Discussion(0)
No comments yet. Be the first to comment.